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Perum Tenascin-C Might Be a Novel
redictor of Left Ventricular Remodeling
nd Prognosis After Acute Myocardial Infarction
kira Sato, MD,* Kazutaka Aonuma, MD,† Kyoko Imanaka-Yoshida, MD,‡ Toshimichi Yoshida, MD,‡
itsuaki Isobe, MD,§ Daisuke Kawase, Noriaki Kinoshita, PHD, Yoshio Yazaki, MD,¶
ichiaki Hiroe, MD#
okosuka, Tsukuba, Tsu, Tokyo, and Gunma, Japan
OBJECTIVES We investigated clinical implications of serum tenascin-C (TN-C) levels in patients with
acute myocardial infarction (AMI).
BACKGROUND Tenascin-C, an extracellular matrix glycoprotein, is not normally expressed in the adult heart,
but transiently appears during pathological conditions and plays important roles in tissue
remodeling.
METHODS Serum TN-C levels were measured by ELISA in 105 AMI patients at various time points,
in 10 old myocardial infarction (OMI) patients, and 20 normal controls.
RESULTS The mean serum TN-C level of AMI patients on admission (63.3  30.1 ng/ml) was
significantly higher than that of controls and OMI (30.9 8.8 ng/ml and 27.4 11.7 ng/ml,
respectively, p  0.01), and peaked at 5 days (83.2  43.0 ng/ml). Follow-up examination
(mean: 43.9 19.6 months) revealed that 25 of 105 AMI (23.8%) patients showed left ventricular
(LV) remodeling (20% end-diastolic volume increase), and in 15 (14.3%), major adverse cardiac
events (MACE) were detected. The peak TN-C level was significantly higher in the remodeling
group than the nonremodeling group (112  37 ng/ml vs. 66  29 ng/ml; p  0.0001). By
receiver-operating characteristic (ROC) analysis, TN-C levels clearly discriminated prediction of
LV remodeling and MACE compared with other variables including plasma B-type natriuretic
peptide, creatine kinase-MB, and LV function. Best predictive values of TN-C for remodeling
and MACE were 84.8 and 92.8 ng/ml, respectively. Cox proportional hazards model analysis
showed that TN-C was an important independent predictor of MACE.
CONCLUSIONS The findings suggest that serum TN-C levels might be useful in predicting LV remodeling
and prognosis after AMI. (J Am Coll Cardiol 2006;47:2319–25) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.033College of Cardiology Foundation
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left ventricular (LV) remodeling following acute myocar-
ial infarction (AMI) is a major predictor of morbidity and
ortality for overt congestive heart failure (CHF) and
ife-threatening arrhythmias (1). It occurs in an appreciable
roportion of patients with AMI successfully treated with
rimary percutaneous transluminal coronary angioplasty
espite sustained patency of the infarct-related artery and
reservation of regional and global LV functions (2). There-
ore, it may be important to identify patients at risk of LV
emodeling to prevent LV dilation after AMI. It has been
eported that infarct size, anterior infarct location, per-
usion status of the culprit lesion, and CHF on admission
re major predictors of LV dilation. Recently, several
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Manuscript received January 23, 2006; revised manuscript received March 7, 2006,
ccepted March 15, 2006.actors, including B-type natriuretic peptide (BNP), car-
iac troponin I, and high-sensitivity C-reactive protein,
ave been examined as potential predicting biomarkers of
V remodeling (2).
Tenascin-C (TN-C) is an extracellular matrix protein
pecifically expressed at high levels during embryonic devel-
pment, wound healing, and cancer invasion and involved
n regulation of cell behavior during tissue remodeling in
arious tissues (3–6). In the heart, TN-C is normally
xpressed in early-stage embryos, playing important roles in
evelopment of the myocardium, valves, and coronary
essels; but is not detected in adults (7). However, it is
e-expressed under pathologic conditions such as AMI
8,9), hibernation (10), and myocarditis (11–13) and is
losely associated with tissue injury and inflammation.
ased on these specific expression patterns, we recently
evealed that immunostaining of myocardial tissues (11,13)
nd immunoscintigraphic imaging (12) for TN-C could be
seful in diagnosis of active myocarditis. Furthermore, using
n experimental model of myocardial infarction, we found
hat TN-C transiently appeared during acute stages, with
everal significant roles in myocardial tissue remodeling
8,14). Therefore, we hypothesized that TN-C expression
evels might be useful for the diagnosis and determination of
V remodeling following AMI. In the present study, to
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Tenascin-C After Myocardial Infarction June 6, 2006:2319–25larify clinical implications of TN-C levels in patients with
MI, we assessed serum TN-C concentrations with refer-
nce to cardiac function and patient outcomes.
ETHODS
tudy population. We prospectively studied 105 patients
ith AMI (73 men and 32 women, mean age 66 12 years)
dmitted to Yokosuka Kyosai Hospital between January
000 and March 2003, 10 patients with old myocardial
nfarction (OMI) (8 men and 2 women, mean age 66  9
ears), and 20 normal volunteers (14 men and 6 women,
ean age 49 15 years). Inclusion criteria for this study for
MI patients were as follows: 1) chest pain 30 min in
uration and present within 12 h after onset of symptoms;
) ST-segment elevation 0.1 mV with two contiguous
lectocardiographic leads; 3) total occlusion of the infarct-
elated artery; 4) elevated creatine kinase (CK)-MB isoen-
ymes within 12 h of chest pain; and 5) successful primary
oronary angioplasty (defined as Thrombolysis In Myocar-
ial Infarction flow grade 3 [15] and residual diameter
tenosis30%). Clinical characteristics of the AMI patients
n hospital admission are described in Table 1. The drugs
isted in Table 2 were administered at the time of admission
ccording to the discretion of the treating physicians.
ritten informed consent was obtained from all patients
nd volunteers, and the study protocol was approved by our
nstitutional review board.
able 1. Clinical Characteristics of 105 Patients With Acute
yocardial Infarction Undergoing Successful Primary
ercutaneous Coronary Intervention
ge (yrs) 66  12
ale (%) 70
isk factors
Current smoker (%) 53
Diabetes (%) 15
Hypertension (%) 39
Hyperlipidemia (%) 48
nfarct location
Anterior (%) 54
Inferior (%) 26
Lateral (%) 20
Abbreviations and Acronyms
AMI  acute myocardial infarction
CHF  congestive heart failure
LV  left ventricle
LVEDV  left ventricular end-diastolic volume
LVESV  left ventricular end-systolic volume
MACE  major cardiac adverse events
MMP  matrix metalloproteinase
OMI  old myocardial infarction
ROC  receiver-operating characteristic
SPECT  single photon emission computerized
tomography
TDS  total defect score
TN-C  tenascin-CcReperfusion times (h) 6.4  4.7ssay of serum TN-C levels by ELISA. Blood samples
ere centrifuged at 15,000 g for 15 min, and resulting
upernatants were stored at 80°C until analysis. Serum
evels of TN-C with the large subunit containing the C
omain of FNIII repeats were determined using an ELISA
it with two monoclonal antibodies, 4F10TT and 19C4MS
IBL, Gunma, Japan), as previously described (16).
iochemical analyses. Serum CK-MB levels were ana-
yzed by enzymatic means and plasma BNP concentrations
ere measured using a specific immunoradiometric com-
ercial assay kit (Shionogi, Japan).
adionuclide imaging. Electrocardiogram-gated myo-
ardial single-photon emission computerized tomogra-
hy (SPECT) with 99mTc-tetrofosmin was performed on
dmission and 6 months later. Imaging was performed at
est in the supine position 1 h after intravenous injection
f 740 MBq 99mTc-tetrofosmin as the radiotracer at both
ime points using a double-detector SPECT system
Picker Prism 2000 XP, Shimadzu Corp., Kyoto, Japan)
quipped with a low-energy high-resolution collimator.
eventy-two projection data were obtained with a 64 
4 matrix over 360°. Data were acquired for 40 s for each
rojection. The total acquisition time was approximately
4 min. Images were gated at 16 frames per cardiac cycle
ith an R-wave trigger and standard parameters similar
o the left ventricular ejection fraction (LVEF), left
entricular end-diastolic volume (LVEDV), and left
entricular end-systolic volume (LVESV), which are
able 2. Clinical Characteristics of Patients in the Remodeling
nd Non-Remodeling Groups
Non-Remodeling
(n  80)
Remodeling
(n  25) p Value
ge (yrs) 66.0  12.3 64.6  11.1 0.401
nterior MI (%) 48 62 0.361
eperfusion times (h) 6.4  5.1 6.6  4.0 0.476
BP (mm Hg) 122  15 117  15 0.436
eak TN-C (ng/ml) 66  29 112  37 0.0001
eak CK-MB (IU/I) 250  149 419  227 0.0011
NP on day 5 (pg/ml) 104  73 190  91 0.0001
NP on day 28 (pg/ml) 97  66 233  198 0.0003
eft ventricular
EDV on admission (ml) 93  25 109  33 0.051
ESV on admission (ml) 45  17 60  22 0.013
EF on admission (%) 52  11 46  7 0.033
TDS on admission 13.2  6.8 19.1  4.5 0.0001
rugs
ACE inhibitors 57% 73% 0.172
ARB 23% 12% 0.24
Calcium antagonists 21% 19% 0.899
Diuretics 21% 34% 0.205
Beta-blockers 31% 27% 0.738
alues are means  SD.
ACE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocker;
NP  B-type natriuretic peptide; CK-MB  creatine kinase-MB; EDV 
nd-diastolic volume; EF  ejection fraction; ESV  end-systolic volume; MI 
yocardial infarction; SBP  systolic blood pressure; TDS  total defect score.
N-C  tenascin-C.ommercially available with Germano software (17). The
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June 6, 2006:2319–25 Tenascin-C After Myocardial InfarctionPECT images of the LV were divided into 17 segments
ccording to the American Heart Association/American
ollege of Cardiology recommendations (18). Short-axis
lices were separated into eight segments at the basal and
idventricular levels, and the apical portion of one segment
as evaluated using vertical long-axis slices. Each segment
as visually scored according to four grades (0  normal
ptake; 1  mildly decreased uptake; 2  moderately
ecreased uptake; 3  severely decreased uptake), and total
efect scores (TDS) were calculated by summation.
efinition of LV remodeling and monitoring of clinical
vents. The LV remodeling was defined as an increase in
nd-diastolic volume at six months after infarction of20%
n comparison with that based on measurements in individ-
al patients, according to Bolognese et al. (19). Major
dverse cardiac events (MACE), defined as cardiac death,
onfatal AMI, and hospitalization for CHF, were the
rimary outcomes for the present analysis. After hospital
ischarge, all patients on medication were monitored at our
utpatient clinic for up to 5.5 years.
mmunohistochemistry of TN-C. Immunostainings of
eart tissues obtained from three AMI, three OMI, and
hree noncardiac disease autopsy cases were performed as
reviously described (20) using two anti–TN-C mouse
onoclonal antibodies. In brief, after treatment with
epsin for 10 min or heating in an autoclave for antigen
etrieval, sections were incubated with antibody clone
F10TT (1 g/ml) or 6C6MS (10 g/ml), and then
rocessed using an LSAB kit (Dako Japan, Kyoto,
apan). The 6C6MS antibody recognizes the same FNIII
epeat of TN-C as 19C4MS antibody but gives more
ntense immunostaining than 19C4MS in paraffin-
mbedded tissues.
tatistical analysis. The multivariate analysis included all
isk factors with probability values of 0.05 in a back-
ard stepwise regression model. Receiver-operating
haracteristic (ROC) analysis was used to determine
ptimal cut-off values of clinical variables for predictions
f LV remodeling and MACE. The ROC curve repre-
ents relationships between sensitivity and specificity by
lotting true-positive rates against false-positive rates as
he cut-off level of the model varies. The area under the
OC curve (AUC) provides a measure of overall accuracy
hat is independent of decision criterion. The best cut-off
alue was defined as the point with the highest sum of
ensitivity and specificity. Evaluation of statistical differ-
nces between groups was determined using Kruskal-
allis analysis, the Mann-Whitney U test and one-way
nalysis of variance. Correlations were estimated using
he Spearman rank correlation test. Event-free survival
urves for MACE were constructed using the Kaplan-
eier method, and statistical differences between curves
ere assessed using the log rank test. Values of p  0.05
ere considered significant. TESULTS
xpression of TN-C in human myocardium following
yocardial infarction. Positive immunostainings with the
wo monoclonal antibodies, 6C6MS and 4F10TT, were
bserved in infarct lesions of myocardia in AMI patients. In
ontrast, scar tissue in OMI patients and normal myocardia
ere negative with both antibodies (Fig. 1).
equential changes in serum TN-C concentrations follow-
ng AMI. The peak TN-C levels in AMI patients (85.9 
1.7 ng/ml) were significantly higher than in OMI (27.4 
1.7 ng/ml) (p 0.01) and control patients (30.9 8.8 ng/ml)
p  0.01) (Fig. 2). The TN-C levels were not statistically
istinguishable between control and OMI patients. Whereas
K-MB levels peaked within 12 h and rapidly decreased
ithin 5 days following infarction, serum TN-C levels were
levated on admission (63.3  30.1 ng/ml), peaked at day 5
83.2  43.0 ng/ml), and then gradually decreased, al-
hough they remained elevated at day 28 (51.8  17.8
g/ml) (Fig. 3).
omparison of clinical characteristics and LV parameters
etween remodeling and nonremodeling groups. Out of
05 patients, 25 (23.8%) showed LV remodeling at 6
onths. During the follow-up period (mean 43.9  19.6
onths), 15 MACE (14.3%) including 8 deaths and 7
ospitalizations for worsening heart failure were observed.
ncidence of MACE in the LV remodeling group was
igher (12 of 25) than in the nonremodeling group (3 of 80)
p  0.01).
Clinical characteristics and LV parameters of the study
atients are shown in Table 2. There were no significant
ifferences in age, perfusion time, infarct location, systolic
lood pressure, and use of cardiovascular medications be-
ween the two groups. Peak TN-C levels were significantly
igher in the remodeling group than in the nonremodeling
roup (112  37 vs. 66  29; p  0.0001). Peak CK-MB,
VESV and total defect scores on admission, and BNP
evels on days 5 and 28 after onset of AMI were also
ignificantly higher in the remodeling group than in the
onremodeling group, whereas LVEF on admission was
ignificantly lower in the remodeling group. No siginificant
elationship was found between peak TN-C and peak
K-MB or total defect score.
OC analysis of clinical variables for predicting LV
emodeling and MACE. We performed ROC analysis of
he following clinical variables: peak serum TN-C levels and
lasma BNP levels on days 5 and 28 after AMI and peak
K-MB, LVEDV, LVESV, and LVEF on admission for
rediction of LV remodeling and MACE (Table 3). For
rediction of LV remodeling, the AUC of the peak serum
N-C level was 0.849, and highest among the analyzed
ariables. The best cut-off value of serum TN-C for pre-
iction of LV remodeling was 84.8 ng/ml, with a sensitivity
f 84% and specificity of 77%.
For prediction of MACE, the AUC of the peak serumN-C level was 0.788, which was also higher than any other
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Tenascin-C After Myocardial Infarction June 6, 2006:2319–25ariables. The best cut-off value for prediction of MACE
as 92.8 ng/ml, with a sensitivity of 73% and specificity of
0%. The AUC of plasma BNP on day 28 was also high for
rediction of MACE (0.783). The best cut-off value of
NP level was 163 pg/ml with a sensitivity of 80% and
pecificity of 59%.
igure 1. Representative microscopic images of tenascin-C expression in a
nfarction (AMI) patient 36 h after myocardial infarction (B, E, H), and an
D, E, F) immunolabeling with antibody clones 4F10TT and (G, H, I)
bserved in the infarcted myocardial lesion of the AMI patients. Bar  1
igure 2. Comparisons of serum tenascin-C (TN-C) levels between acutes
yocardial infarction (AMI), old myocardial infarction (OMI), and
ontrol cases. n.s.  not significant.nivariate and multivariate predictors of MACE. Table 4
hows the results of univariate and multivariate Cox pro-
ortional hazards model analyses between 10 variables
elated to MACE. In the univariate analysis, the peak
N-C level, plasma BNP level on days 5 and 28, LVESV,
VEF, and total defect scores on admission were predictive
actors. According to multivariate analysis, peak TN-C level
as the most important independent predictor of MACE
uring a follow-up period of up to 5.5 years after infarction.
lasma BNP level on day 28 was also a significant predictor
f MACE.
aplan-Meier analysis. During the follow-up period (mean
3.9  19.6 months), there were five deaths and five
ospitalizations for worsening heart failure in patients with
N-C 92.8 ng/ml, and three deaths and two hospitaliza-
ions for worsening heart failure in patients with TN-C
92.8 ng/ml. Kaplan-Meier MACE demonstrated the
igher risks of death and hospitalization of patients with
N-C92.8 ng/ml than of those with TN-C92.8 ng/ml
p  0.0001).
ISCUSSION
ajor novel findings in the present study were as follows: 1)
erum TN-C levels were significantly elevated during acute
ied human myocardia from a normal case (A, D, G), an acute myocardial
myocardial infarction (OMI) patient (C, F, I). (A, B, C) H & E staining;
S. Positive immunostainings with the two monoclonal antibodies were
m.utops
oldtages after AMI; 2) TN-C levels were significantly higher
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June 6, 2006:2319–25 Tenascin-C After Myocardial Infarctionn the LV remodeling group than in the nonremodeling
roup; and 3) AMI patients with high TN-C levels were at
uch higher risk of MACE for up to 5.5 years. Thus, serum
N-C levels in acute stages following AMI might be a
redictive biomarker of LV remodeling during the recovery
hase and prognosis.
levated serum TN-C levels in AMI patients. Using rat
nd mouse myocardial infarction models, we previously
eported that TN-C was synthesized during acute stages by
nterstitial fibroblasts in the border zone myocardium sur-
ounding infarcted lesions (8) and could play several impor-
ant roles in myocardial repair (8,14,21). In the present
aper, we demonstrated that serum TN-C levels in AMI
atients were significantly higher than those in OMI
atients and controls. Immunostaining of autopsied speci-
ens confirmed expression of TN-C in human myocardium
n acute stages following infarction, whereas no expression
as detected in normal myocardium or in scar tissues of
MI patients. Therefore, TN-C synthesized in infarcted
yocardium could enter the bloodstream and cause eleva-
ion of serum TN-C levels in AMI patients. In various
issue injuries, TN-C molecules are synthesized by intersti-
ial cells residing in injured sites. While molecules are
eposited in extracellular spaces and regulate cell behavior in
he local environment, soluble forms might also be released
igure 3. Serial changes in serum tenascin-C (TN-C) and creatine kinase
CK)-MB levels in patients with acute myocardial infarction (AMI).
alues represent the mean and standard error. Serum TN-C levels were
levated on admission, peaked at day 5, and then gradually decreased
A). In contrast, CK-MB levels peaked within 12 h and then rapidly
ecreased (B).nto body fluids. For example, TN-C levels in synovial fluid Arom patients with osteoarthritis (16) and aseptic loosening
fter arthroplasty (22) and in serum of patients with hepatic
brosis (23) are reported to increase in correlation with
isease activity.
In our AMI patients, significantly elevated TN-C levels
ere noted within 24 h after onset. Levels peaked at day 5
nd then gradually decreased. This time course of serum
N-C levels was previously shown to correspond to local
xpression of TN-C in infarcted myocardia of humans (9)
nd rats (8), as detected by immunohistochemistry. It is
oteworthy that the peak of serum TN-C occurred later
han that for CK-MB, and persisted much longer. Further-
ore, peaks of TN-C did not significantly correlate with
otal defect scores on myocardial SPECT with 99mTc-
etrofosmin or with peaks of CK-MB. These results indi-
able 3. Prognostic Value of Each Clinical Variable in
redicting LV Remodeling and Cardiac Events According to
eceiver-Operating Characteristic Analysis
AUC
Cut-Off
Value
Sensitivity
(%)
Specificity
(%)
V remodeling
Peak TN-C (ng/ml) 0.849 84.8 84 77
BNP on day 5
(pg/ml)
0.817 138 92 71
BNP on day 28
(pg/ml)
0.769 143 76 67
Peak CK-MB (IU/I) 0.743 322 76 71
LVEDV (ml) 0.646 101 64 70
LVESV (ml) 0.684 53 72 57
LVEF (%) 0.706 48 76 57
ardiac events
Peak TN-C (ng/ml) 0.788 92.8 73 80
BNP on day 5
(pg/ml)
0.760 148 80 59
BNP on day 28
(pg/ml)
0.783 163 80 65
Peak CK-MB (IU/l) 0.669 335 73 67
LVEDV (ml) 0.640 102 60 62
LVESV (ml) 0.686 55 73 54
LVEF (%) 0.689 47 67 60
UC  area under the receiver-operating characteristic curve; LV  left ventricular;
VEDV  left ventricular end-diastolic volume; LVESV  left ventricular end-
ystolic volume; EF  ejection fraction; other abbreviations as in Table 2.
able 4. Univariate and Multivariate Analyses of the Value of
ach Variable in Predicting Cardiac Events
Predictive Factors
During the
Acute Phase
Univariate Multivariate
Chi-Square p Value Chi-Square p Value
ge 3.13 0.076
eperfusion time 1.38 0.238
eak CK-MB 3.01 0.082
eak TN-C 14.8 0.0001 10.82 0.001
NP on day 5 4.32 0.037
NP on day 28 7.94 0.004 4.23 0.039
VEDV 3.61 0.057
VESV 8.76 0.003 0.36 0.543
VEF 6.96 0.008 0.76 0.381
otal defect scores 6.51 0.011 0.03 0.852bbreviations as in Tables 2 and 3.
c
c
b
h
w
i
t
e
s
i
T
c
r
w
T
l
t
i
c
o
m
f
m
C
v
s
a
a
b
g
A
I
v
l
M
t
r
p
p
a
(
M
(
v
l
(
n
b
T
d
p
o
w
a
p
b
(
e
p
c
r
a
p
C
s
r
f
p
l
p
a
s
p
F
c
r
r
R
Y
U
M
R
1
2324 Sato et al. JACC Vol. 47, No. 11, 2006
Tenascin-C After Myocardial Infarction June 6, 2006:2319–25ate that elevation of TN-C levels might not directly reflect
ardiomyocyte death. Synthesis of TN-C by cardiac fibro-
lasts is stimulated by various cytokines, growth factors,
ypoxia, acidosis, mechanical stress, and angiotensin II (21),
hich could be closely related to myocardial injury and
nflammation during the wound healing process. Although
he infarct size could be one of major determinants of TN-C
xpression levels, which might reflect interstitial response
econdary to myocardial injury, some other factors of
ndividual patients might also influence TN-C expression.
N-C as a marker for LV remodeling and long-term
linical outcomes. Most importantly, patients with LV
emodeling showed higher peak TN-C levels than patients
ithout LV remodeling, and patients with higher peak
N-C levels had a greater incidence of MACE and worse
ong-term prognosis. A previous report revealed that pa-
ients with significant LV remodeling six months after
nfarction had worse long-term clinical outcomes (2). Be-
ause TN-C levels peaked within one week after infarction,
ur results suggest that TN-C could be an early predictive
arker for future ventricular remodeling.
One of the major determinants of ventricular remodeling
ollowing AMI could be infarct size (2,24). Therefore,
yocyte injury markers such as cardiac troponin I and T,
K, and CK isoforms appear to be useful in predicting late
entricular dilation (2). It was also suggested that the
ystemic inflammatory marker C-reactive protein (25,26)
nd neurohormones secreted by cardiomyocytes, including
trial natriuretic peptide (27) and BNP (28), are further
iomarkers of ventricular remodeling. A recent report sug-
ested that plasma BNP levels at three to four weeks after
MI could be independent predictors of cardiac death (29).
n the present study, our analysis of the prognostic value of
arious clinical variables also supported the possibility that
arge infarction and high plasma BNP levels might predict
ACE.
Left ventricular remodeling involves multi-step reac-
ions which orchestrate structural alteration and rear-
angement of cells and connective tissues. During these
rocesses, disproportionate activation of matrix metallo-
roteinases (MMPs) has recently received increasing
ttention in progression of unfavorable tissue remodeling
30 –33). Several reports have suggested that deletions of
MP2 and MMP9 attenuate ventricular remodeling
34 –36) and that MMPs could act as biomarkers of
entricular remodeling (37–39).
Tenascin-C has many biologic effects, including regu-
ation of cell activity during early stages of tissue repair
4,8,11,14,40). It up-regulates MMP expression in a
umber of cell types (41,42) and inhibits strong linkages
etween cardiomyocytes and connective tissues (8,21).
herefore, excessive amounts of TN-C might cause
isproportionate MMP activation, which would lead to
rogressive degradation of connective tissues and slippage
f myocytes within the LV wall, finally resulting in LV
all thinning and dilation. On the other hand, TN-Clso has the potential to promote myocardial repair and
revent ventricular dilation by recruitment of myofibro-
lasts and enhancement of collagen fiber contraction
14,43). Thus, the effects of TN-C on ventricular remod-
ling are not simple but rather are bidirectional. In the
resent study, we found that high levels of serum TN-C
ould be related to a greater incidence of ventricular
emodeling and poor prognosis, suggesting that excessive
nd sustained increments of TN-C could cause inappro-
riate reconstruction of infarcted ventricular walls.
linical implications and limitations. This preliminary
tudy suggests that serum TN-C might be a novel marker
eflecting active structural remodeling in the myocardium
ollowing infarction, with high TN-C levels at acute stages
ossibly predicting progression of LV remodeling.
However, despite the findings, the current study has some
imitations. First, the sample size was relative small. Second,
rognosis of our AMI patients receiving primary coronary
ngioplasty was good, and there were only eight deaths and
even hospitalizations due to heart failure out of 105
atients during the follow-up period of 3 to 5.5 years.
urther large-scale prospective investigations and careful
omparisons with other clinical parameters are therefore
equired to confirm the predictive ability of TN-C in LV
emodeling and MACE.
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